Overview

Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer

Status:
Completed

Trial end date:
2014-04-01

Target enrollment:

Participant gender:

Summary

If AZD6244 is able to increase ER expression in ER-negative/low cancers then it may be possible to effectively use hormonal therapy in these patients resulting in improved outcomes. The investigators propose a single-arm Simon two-step study to examine whether treatment with AZD6244 will result in increased ER expression in ER-negative/low primary breast tumors.

Phase:

Early Phase 1

Details

Lead Sponsor:

University of Miami
University of Miami Sylvester Comprehensive Cancer Center

Treatments:

Estrogen Antagonists
Estrogen Receptor Modulators
Estrogens